Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Consumer News and Business Channel
This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.
Read at original outlet ↗

